37 Network Meta-Analysis Percent Weight CFB to 52 Weeks In all populations studied, semaglutide 2.4 mg was associated with a greater percentage weight CFB with 52 weeks of treatment versus all available comparators, except for phentermine 15 mg/topiramate 92 mg in the T2DM population
Begin Your Journey to a Healthier You With GLP-1 in Orange County, CA Lets talk about your goals
Results The proportions of patients who discontinued study drug in Studies 2, 3, and 4 was 16.0% for the WEGOVY-treated group and 19.1% for the placebo-treated group, and 6.8% of patients treated with WEGOVY and 3.2% of patients treated with placebo discontinued treatment due to an adverse reaction [see Adverse Reactions (6.1)]
Most users report improvements in energy levels, recovery time, sleep quality, and overall body composition within 8 to 12 weeks of combined therapy
This improved sensitivity is key to breaking the cycle of overeating and persistent hunger